Sept 11 (Reuters) - Czech generic drugmaker Zentiva
said on Thursday that private equity group Advent
International had agreed to sell the company to rival GTCR for
an undisclosed value.
The Financial Times had first reported the deal on
Wednesday, saying it was worth 4.1 billion euros ($4.80
billion).
($1 = 0.8540 euros)